Responsiveness of quality‐of‐life measures in patients with peripheral vascular malformations: the OVAMA project

Max M. Lokhorst, Sophie E.R. Horbach, Milton Waner, O T.M., C.J.M. van der Vleuten, Lidwine B. Mokkink, Chantal M.A.M. van der Horst, Phyllis I. Spuls

British Journal of Dermatology · 2019 · 20 citations · 26 references

DOIFull text

Open access

Abstract

Our findings suggest that the SF-36 and Skindex-29 seemed unresponsive to change in QoL. This suggests that alternative PROMs are needed to measure - and ultimately improve - QoL in patients with vascular malformations. What's already known about this topic? Quality of life is often impaired in patients with vascular malformations. Quality of life is considered a core outcome domain for evaluating treatment of vascular malformations. To measure the effect of treatment on quality of life, a patient-reported outcome measure is required that is responsive to changes in quality of life. What does this study add? This is the first study assessing the responsiveness of quality-of-life measures in patients with vascular malformations. The results seem to indicate that the Medical Outcomes Study Short Form 36 (SF-36) and Skindex-29 are not responsive to changes in quality of life in patients with vascular malformations. What are the clinical implications of this work? Medical Outcomes Study Short Form 36 (SF-36) and Skindex-29 are not ideal to assess the effect on quality of life over time, of treatment strategies for peripheral vascular malformations.

References

26